SecondWave Systems Announces Professor Paul Peter Tak as New Advisory Board Member and Secures $3M Additional Financing to Accelerate Development of Novel Ultrasound-Based Anti-Inflammatory Therapy
Retrieved on:
Wednesday, March 27, 2024
Research, Medical Devices, Clinical Trials, Health Technology, Public Policy, Government, Biotechnology, White House, Federal Government, Managed Care, Health, Science, ARPA-H, Rheumatoid arthritis, Partnership, Patient, Trial of the century, ARPA, Inflammation, DARPA, Spleen, Pharmaceutical industry
SecondWave Systems, Inc. , a pioneer in the emerging field of bio-ultrasonic medicine, welcomes Professor Paul Peter Tak as the inaugural member of its newly established advisory board.
Key Points:
- SecondWave Systems, Inc. , a pioneer in the emerging field of bio-ultrasonic medicine, welcomes Professor Paul Peter Tak as the inaugural member of its newly established advisory board.
- This new funding enables further advancement of the MINI technology platform for implementation in a pivotal clinical trial for at-home treatment of RA.
- “Despite advances in treatment, there is still a significant unmet need for better treatments for chronic inflammatory diseases, like RA”, said Dr. Tak.
- “One area of unmet need is for therapies that specifically target the cholinergic anti-inflammatory pathway, a natural mechanism in the body that helps control inflammation.